

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bisantrene,Bisantrene DiHCl
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement
Ardena Signs Agreement with Race Oncology Limited to Manufacture RC220
Details : Under the agreement, Ardena will provide additional Good Manufacturing Practice (cGMP)-standard manufacturing capability for Race’s flagship intravenous (IV) formulation of RC220 (bisantrene dihydrochloride).
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 12, 2023
Lead Product(s) : Bisantrene,Bisantrene DiHCl
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Race Oncology
Deal Size : $1.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Sponsor : Race Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Race Executes Global License Agreement with City of Hope to Access FTO IP
Details : Under the agreement, Race will exclusively secure rights to a City of Hope patent application and associated know-how identifying that bisantrene may be the most potent inhibitor of the Fatso/Fat mass and obesity associated (FTO) protein.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
July 10, 2023
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Sponsor : Race Oncology
Deal Size : Undisclosed
Deal Type : Licensing Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Astex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Bisantrene Dihydrochloride is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
July 13, 2022
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Astex Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Race Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Bisantrene Combination for Resistant AML
Details : Bisantrene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 04, 2021
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Race Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable

Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Race Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
Bisantrene for Relapsed /Refractory AML
Details : Bisantrene is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Leukemia, Myeloid, Acute.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 29, 2019
Lead Product(s) : Bisantrene
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Race Oncology
Deal Size : Inapplicable
Deal Type : Inapplicable
